The estimated Net Worth of James Trager is at least $1.55 Million dollars as of 18 June 2024. Dr Trager owns over 456 units of Nkarta stock worth over $969,157 and over the last 4 years he sold NKTX stock worth over $578,987.
Dr has made over 9 trades of the Nkarta stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 456 units of NKTX stock worth $2,554 on 18 June 2024.
The largest trade he's ever made was selling 6,400 units of Nkarta stock on 1 February 2021 worth over $251,200. On average, Dr trades about 2,094 units every 88 days since 2020. As of 18 June 2024 he still owns at least 150,959 units of Nkarta stock.
You can see the complete history of Dr Trager stock trades at the bottom of the page.
Dr. James Trager Ph.D., Ph.D. is the Chief Scientific Officer at Nkarta.
Dr D is 57, he's been the Chief Scientific Officer of Nkarta since . There are 1 older and 4 younger executives at Nkarta. The oldest executive at Nkarta, Inc. is Paul J. Hastings, 61, who is the CEO, Pres & Director.
James's mailing address filed with the SEC is C/O NKARTA, INC., 1150 VETERANS BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 4 years, insiders at Nkarta have traded over $2,620,353 worth of Nkarta stock and bought 14,255,554 units worth $205,999,973 . The most active insiders traders include Plc Gsk, Ali Behbahani, and Holdings A/S Novo. On average, Nkarta executives and independent directors trade stock every 24 days with the average trade being worth of $1,501,195. The most recent stock trade was executed by Alicia J. Hager on 16 July 2024, trading 3,396 units of NKTX stock currently worth $27,168.
Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Nkarta executives and other stock owners filed with the SEC include: